Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celldex Therapeutics Inc Announces Pricing Of $90 Million Public Offering Of Common Stock


Tuesday, 5 Feb 2013 08:15pm EST 

Celldex Therapeutics Inc announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the public of $7.50 per share for an aggregate offering of $90,000,000 of common stock. The proceeds to Celldex from this offering are expected to be approximately $84,345,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex. Celldex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,800,000 additional shares of common stock. All of the shares in the offering are to be sold by Celldex. The offering is expected to close on or about February 11, 2013. Jefferies & Company, Inc. and Leerink Swann LLC are acting as joint book-running managers of the offering. Oppenheimer & Co., Wedbush PacGrow Life Sciences, Brean Capital and Roth Capital Partners, LLC are acting as co-managers of the offering. Celldex anticipates using the net proceeds from the offering to fund Celldex's clinical trials of its product candidates and for working capital and other general corporate purposes. 

Company Quote

13.57
-0.5 -3.55%
4:00pm EDT